Micromet (NASDAQ: MITI), Monsanto Co. (NYSE: MON), Optimer Pharmaceuticals (NASDAQ: OPTR), Integrated Device Technology, Inc. (NASDAQ: IDTI), InterMune, Inc. (NASDAQ: ITMN) and Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had ratings on them reiterated by analysts.
Micromet (MITI) had its “Buy” rating reiterated by Needham & Company.
Monsanto Co. (MON) had its “Hold” rating reiterated by Jefferies Group (NYSE:JEF).
Optimer Pharmaceuticals (OPTR) had its “Buy” rating reiterated by Needham & Company.
Integrated Device Technology, Inc. (IDTI) had its “Buy” rating reiterated by Canaccord Genuity.
InterMune, Inc. (ITMN) had its “Neutral” rating reiterated by Goldman Sachs (NYSE:GS).
Lexicon Pharmaceuticals, Inc. (LXRX) had its “Buy” rating reiterated by Needham & Company.
Showing posts with label Micromet. Show all posts
Showing posts with label Micromet. Show all posts
Monday, January 9, 2012
Friday, January 6, 2012
Micromet (MITI) (ACHC) (ASNA) (BOKF) (BUD) (CERN) Ratings, Price Targets
Micromet (NASDAQ: MITI), Acadia Healthcare (NASDAQ: ACHC), Ascena Retail Group Inc. (NASDAQ: ASNA), BOK Financial Co. (NASDAQ: BOKF), Anheuser Busch (NYSE: BUD) and Cerner Corp. (NASDAQ: CERN) ratings and price targets.
Micromet (MITI) had its “buy” rating reiterated by Needham & Company.
Acadia Healthcare (ACHC) is now covered by Jefferies Group (NYSE:JEF). They have a “buy” rating on the company.
Ascena Retail Group Inc. (ASNA) had its price target raised by FBR Capital from $30.00 to $34.00. They have a “market perform” rating on the company.
BOK Financial Co. (BOKF) was downgraded by Stifel Nicolaus from a “buy” rating to a “hold” rating.
Anheuser Busch (BUD) was downgraded by ING Group from a “buy” rating to a “hold” rating.
Cerner Corp. (CERN) was upgraded by Deutsche Bank (NYSE:DB) from a “hold” rating to a “buy” rating.
Micromet (MITI) had its “buy” rating reiterated by Needham & Company.
Acadia Healthcare (ACHC) is now covered by Jefferies Group (NYSE:JEF). They have a “buy” rating on the company.
Ascena Retail Group Inc. (ASNA) had its price target raised by FBR Capital from $30.00 to $34.00. They have a “market perform” rating on the company.
BOK Financial Co. (BOKF) was downgraded by Stifel Nicolaus from a “buy” rating to a “hold” rating.
Anheuser Busch (BUD) was downgraded by ING Group from a “buy” rating to a “hold” rating.
Cerner Corp. (CERN) was upgraded by Deutsche Bank (NYSE:DB) from a “hold” rating to a “buy” rating.
Thursday, August 18, 2011
TiVo (TIVO) (KOS) (LPSN) (MITI) (NFP) (ROVI) (VMW) Get New Coverage
TiVo Inc (NASDAQ: TIVO), Kosmos Energy Ltd (NYSE: KOS), LivePerson Inc (NASDAQ: LPSN), Micromet (NASDAQ: MITI), National Financial Partners Corp. (NYSE: NFP), Rovi Corp (NASDAQ: ROVI) and VMware, Inc. (NYSE: VMW) getting new analyst coverage.
Merriman Curhan Ford initiated coverage on TiVo Inc. (TIVO). They placed a “Buy” rating on the company.
RBC Capital initiated coverage on Kosmos Energy Ltd (KOS). They placed an “Outperform” rating and a price target of $16.00 on the company.
Ladenburg Thalmann initiated coverage on LivePerson Inc. (LPSN). They placed a “buy” rating and a $16.00 price target on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Micromet (MITI). They placed a “Neutral” rating on the company.
Keefe, Bruyette & Woods, Inc. initiated coverage on National Financial Partners Corp. (NYSE: NFP). They placed an “Outperform” rating on the company.
Merriman Curhan Ford initiated coverage on Rovi Corp. (ROVI). They placed a “Buy” rating on the company.
Sanford C. Bernstein initiated coverage on VMware, Inc. (VMW). They placed a “Market Perform” rating on the company.
Merriman Curhan Ford initiated coverage on TiVo Inc. (TIVO). They placed a “Buy” rating on the company.
RBC Capital initiated coverage on Kosmos Energy Ltd (KOS). They placed an “Outperform” rating and a price target of $16.00 on the company.
Ladenburg Thalmann initiated coverage on LivePerson Inc. (LPSN). They placed a “buy” rating and a $16.00 price target on the company.
Goldman Sachs (NYSE:GS) initiated coverage on Micromet (MITI). They placed a “Neutral” rating on the company.
Keefe, Bruyette & Woods, Inc. initiated coverage on National Financial Partners Corp. (NYSE: NFP). They placed an “Outperform” rating on the company.
Merriman Curhan Ford initiated coverage on Rovi Corp. (ROVI). They placed a “Buy” rating on the company.
Sanford C. Bernstein initiated coverage on VMware, Inc. (VMW). They placed a “Market Perform” rating on the company.
Thursday, May 19, 2011
Coverage on (GLUU) (HEV) (JRCC) (MITI) (MXWL) Initiated By Analysts
Coverage on shares of Glu Mobile Inc. (NASDAQ: GLUU), Ener1, Inc. (NYSE: HEV), James River Coal Company (NASDAQ: JRCC), Micromet (NASDAQ: MITI) and Maxwell Technologies (NASDAQ: MXWL) was initiated by analysts.
ThinkEquity initiated coverage on Glu Mobile Inc. (GLUU). They placed a “buy” rating on the company.
Pacific Crest initiated coverage on Ener1, Inc. (HEV). They placed a “sector perform” rating on the company.
Deutsche Bank (NYSE:DB) initiated coverage on James River Coal Company (JRCC). They placed a “buy” rating on the company.
William Blair initiated coverage on Micromet (MITI). They placed an “outperform” rating on the company.
Pacific Crest initiated coverage on Maxwell Technologies (MXWL). They placed an “outperform” rating on the company.
ThinkEquity initiated coverage on Glu Mobile Inc. (GLUU). They placed a “buy” rating on the company.
Pacific Crest initiated coverage on Ener1, Inc. (HEV). They placed a “sector perform” rating on the company.
Deutsche Bank (NYSE:DB) initiated coverage on James River Coal Company (JRCC). They placed a “buy” rating on the company.
William Blair initiated coverage on Micromet (MITI). They placed an “outperform” rating on the company.
Pacific Crest initiated coverage on Maxwell Technologies (MXWL). They placed an “outperform” rating on the company.
Thursday, January 6, 2011
Micromet's (NASDAQ:MITI) Cash Position Should Bring it Through 2013
There are some potential catalysts out there for Micromet (NASDAQ:MITI) which could help them in the short term, such as new trial initiations and ongoing trial updates. It appears they have enough capital to undergird development through 2013.
Needham said, "In the near-term, we believe that data presentations, progress update from the ongoing trials and new trial initiations may drive the stock higher: the ongoing pivotal trial is expected to take 2 years to complete enrollment. In the long-term, we favor the bispecific antibody platform (8 products in development/12 candidates in early-stage), focused on established drug targets and recruitment of the immune system, as a new and potent next-generation antibody strategy. With a projected cash burn of $55-60MM/year, we believe the Company may have sufficient resources to support clinical development until the pivotal data in 2013."
Needham & Company maintains a "Buy" rating on Micromet, which closed Wednesday at $8.29, gaining $0.18, or 2.22 percent. Needham has a price target of $13 on them.
Needham said, "In the near-term, we believe that data presentations, progress update from the ongoing trials and new trial initiations may drive the stock higher: the ongoing pivotal trial is expected to take 2 years to complete enrollment. In the long-term, we favor the bispecific antibody platform (8 products in development/12 candidates in early-stage), focused on established drug targets and recruitment of the immune system, as a new and potent next-generation antibody strategy. With a projected cash burn of $55-60MM/year, we believe the Company may have sufficient resources to support clinical development until the pivotal data in 2013."
Needham & Company maintains a "Buy" rating on Micromet, which closed Wednesday at $8.29, gaining $0.18, or 2.22 percent. Needham has a price target of $13 on them.
Subscribe to:
Posts (Atom)